Published in

American Society of Hematology, Blood, 16(126), p. 1921-1924, 2015

DOI: 10.1182/blood-2015-05-647925

Links

Tools

Export citation

Search in Google Scholar

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Journal article published in 2015 by Davide Rossi, Lodovico Terzi-Di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R. Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Francesco Forconi, Luca Laurenti, Ilaria Del Giudice and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Key Points CLL patients harboring mutated IGHV genes but neither 11q or 17p deletion experience durable remission after frontline FCR.